Fluidigm Announces First Quarter 2019 Financial Results
May 02, 2019 16:05 ET
|
Fluidigm Corporation
First quarter revenue increased 19 percent to $30.1 million Mass cytometry revenue growth of 110 percent in first quarter Strong mass cytometry and Imaging Mass Cytometry instrument adoption First...
Fluidigm Showcases New Product Innovations and Research Presentations at the 2019 American Association for Cancer Research (AACR) Meeting
March 28, 2019 08:45 ET
|
Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., March 28, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive...
Fluidigm to Participate in Upcoming Investor Conferences
February 22, 2019 17:30 ET
|
Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., Feb. 22, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive...
Fluidigm Announces Fourth Quarter and Full Year 2018 Financial Results
February 07, 2019 16:05 ET
|
Fluidigm Corporation
Fourth quarter revenue increased 17 percent to $32.3 million Mass cytometry revenue growth of 48 percent in fourth quarter Full year 2018 revenue increased 11 percent to $113.0 millionIncluding...
Fluidigm Introduces REAP-Seq for Multi-Omic Single-Cell Analysis on the C1
January 31, 2019 08:30 ET
|
Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., Jan. 31, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), a leader in mass cytometry and microfluidics technologies, today announced the introduction of a...
Fluidigm Announces Conference Call and Webcast of Fourth Quarter and Full Year 2018 Financial Results
January 14, 2019 16:05 ET
|
Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., Jan. 14, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), a leader in mass cytometry and microfluidics technologies, announced today that it will report...
Fluidigm Announces Closing of Public Offering of 9,372,500 Shares of Common Stock Including Full Exercise of Option to Purchase Additional Shares
December 14, 2018 16:05 ET
|
Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., Dec. 14, 2018 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ: FLDM), a leader in mass cytometry and microfluidics technologies, today announced the closing of its...
Fluidigm to Participate in the 30th Annual Piper Jaffray Healthcare Conference
November 12, 2018 16:05 ET
|
Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., Nov. 12, 2018 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ: FLDM), a leader in mass cytometry and microfluidics technologies, announced today that the company’s...
Fluidigm Showcases Immuno-Oncology Innovations for Translational and Clinical Research at SITC 2018
November 08, 2018 08:30 ET
|
Fluidigm Corporation
A comprehensive suite of innovative immuno-oncology applications to improve the future of cancer care SOUTH SAN FRANCISCO, Calif., Nov. 08, 2018 (GLOBE NEWSWIRE) -- Fluidigm Corporation...
Fluidigm Recognized as a Company to Watch in 2019
November 07, 2018 16:11 ET
|
Fluidigm Corporation
Immuno-oncology innovator receives life science people’s choice award SOUTH SAN FRANCISCO, Calif., Nov. 07, 2018 (GLOBE NEWSWIRE) -- BioInformatics Inc., the leading research and advisory firm...